Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 419551
Title Current and future drug targets in weight management
Author(s) Witkamp, R.F.
Source Pharmaceutical Research 28 (2011)8. - ISSN 0724-8741 - p. 1792 - 1818.
DOI http://dx.doi.org/10.1007/s11095-010-0341-1
Department(s) Chair Nutrition and Pharmacology (HNE)
VLAG
Publication type Refereed Article in a scientific journal
Publication year 2011
Keyword(s) 11-beta-hydroxysteroid dehydrogenase type-1 - protein-coupled receptor - cannabinoid cb1 receptor - brown adipose-tissue - placebo-controlled trial - histamine h3 receptor - food-intake - metabolic-disorders - endocannabinoid system - energy-expenditure
Abstract Obesity will continue to be one of the leading causes of chronic disease unless the ongoing rise in the prevalence of this condition is reversed. Accumulating morbidity figures and a shortage of effective drugs have generated substantial research activity with several molecular targets being investigated. However, pharmacological modulation of body weight is extremely complex, since it is essentially a battle against one of the strongest human instincts and highly efficient mechanisms of energy uptake and storage. This review provides an overview of the different molecular strategies intended to lower body weight or adipose tissue mass. Weight-loss drugs in development include molecules intended to reduce the absorption of lipids from the GI tract, various ways to limit food intake, and compounds that increase energy expenditure or reduce adipose tissue size. A number of new preparations, including combinations of the existing drugs topiramate plus phentermine, bupropion plus naltrexone, and the selective 5-HT2C agonist lorcaserin have recently been filed for approval. Behind these leading candidates are several other potentially promising compounds and combinations currently undergoing phase II and III testing. Some interesting targets further on the horizon are also discussed
Comments
There are no comments yet. You can post the first one!
Post a comment
 
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.